Research area
Health & Longevity
Human health, disease, treatment and aging. The largest corpus area supports distinct cancer, neurological and therapeutic navigation.
-
Evidence date ·How can eye care protect sight when cancer spreads to the eye?
Review or Meta-AnalysisWhen cancer spreads to the eye, it most often affects the choroid. A review links longer survival to timely eye care and oncology referral.
-
Evidence date ·Why block two immune brakes together in cancer?
Review or Meta-AnalysisTracked over timeTwo immune checkpoints restrain T cells at different stages. A 2025 mini review explains why one antibody might target both in cancer research.
-
Evidence date ·How MEDI5752 directs CTLA-4 blockade toward activated T cells with PD-1
Peer-Reviewed PaperTracked over timeMEDI5752 favored CTLA-4 blockade on PD-1-positive T cells and showed stronger activity in vivo than separate antibodies used together.
-
Evidence date ·What patients reported about life after engineered immune-cell treatment
Review or Meta-AnalysisIn one study of adults at least a year after immune-cell therapy, physical health scores resembled general-population scores, but mental health scores were lower.
-
Evidence date ·When brain metastases need radiation during ongoing cancer treatment
Review or Meta-AnalysisA 2021 review found no skin toxicity and no clear rise in bleeding or clinically significant radiation necrosis across 77 studies; safety may vary by drug.
-
Evidence date ·Why treating a few tumors may not control cancer elsewhere
Review or Meta-AnalysisA 2021 review asks whether immunotherapy could help control cancer beyond the few tumors treated with focused radiation.
-
Evidence date ·Skin lesions were inflammation while a pelvic mass was cancer
Clinical TrialTracked over timeBiopsies found sarcoid-like inflammation in two skin bumps, while a pelvic mass was confirmed as cancer. Immune-cell mapping revealed shared patterns and clear differences.
-
Evidence date ·What 80 reported cases reveal about confusing inflammation with cancer progression
Review or Meta-AnalysisTracked over timeOf 80 reported cases, 52 did not need the steroid prednisolone, while immunotherapy stopped in 44. The overlap between these groups is unknown.
-
Evidence date ·What did a biopsy reveal about this patient’s skin changes?
Review or Meta-AnalysisTracked over timeA biopsy confirmed cutaneous sarcoidosis during pembrolizumab and chemotherapy. Skin changes resolved after steroids while pembrolizumab continued less often.
-
Evidence date ·One melanoma patient recovered from COVID-19, leaving an open treatment question
Review or Meta-AnalysisA patient with metastatic melanoma recovered from COVID-19 after responding to immunotherapy. A review raises the possibility of continuing it when cancer is controlled.